1.27
Celularity Inc Aktie (CELU) Neueste Nachrichten
NEXGEL to pay $15 million for Celularity regenerative biomaterial portfolio - MSN
Aug Summary: Can Celularity Inc maintain sales growth2026 Drop Watch & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Breakout Move: Can Celularity Inc outperform in the next rally2026 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Bond Watch: What is Celularity Inc Equity Warrants revenue forecastM&A Rumor & Weekly Momentum Picks - baoquankhu1.vn
NEXGEL to Pay $15 Million for Celularity Regenerative Biomaterial Portfolio - MyChesCo
NEXGEL signs agreement to acquire regenerative biomaterial portfolio - MSN
Stock Report: Will Celularity Inc Equity Warrant benefit from AI trends2026 Fed Impact & Precise Entry and Exit Recommendations - baoquankhu1.vn
Targets Report: Will Celularity Inc benefit from government policy2026 AllTime Highs & Long-Term Safe Investment Ideas - baoquankhu1.vn
Celularity strikes up to $35M licensing deal for biomaterials portfolio - MSN
WBB Securities Upgrades Celularity (CELU) - MSN
CelularityFinancial Details - Crunchbase
Buyback Watch: What is Celularity Inc Equity Warrants revenue forecast2026 Update & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
NEXGEL discloses $15M upfront payment for Celularity portfolio By Investing.com - Investing.com Canada
Celularity inks $35m deal for longevity push - Longevity.Technology
NXGL Stock: NEXGEL Signs Deal to Triple Revenue and Turn Profitable With Acquisition of Six Commercial-Stage Regenerative Biomaterial Products - Barchart.com
NEXGEL discloses $15M upfront payment for Celularity portfolio - Investing.com
NEXGEL Announces $15 Million Acquisition of Regenerative Biomaterial Products from Celularity, Expected to Triple Revenue and Drive Profitability - Quiver Quantitative
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities - The Manila Times
Biomaterial deal aims to triple NEXGEL sales and turn profit - Stock Titan
Inside Celularity’s bet on NEXGEL to shake up wound care biomaterials - Stock Titan
Biotechnology company Celularity Inc. (NASDAQ: CELU) recently reaffirmed its strategic commercialization partnership with NEXGEL, INC. (NASDAQ: NXGL). - Bitget
Macro Review: Is Celularity Inc Equity Warrant a speculative investmentIndex Update & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Celularity licenses biomaterials portfolio for up to $35 million By Investing.com - Investing.com Canada
Celularity licenses biomaterials portfolio for up to $35 million - Investing.com Nigeria
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy - Investing News Network
Celularity Inc. Secures $35 Million Strategic License Deal and Strengthens Capital Position to Advance Longevity-Focused Strategy - marketscreener.com
NexGel Acquires Celularity Regenerative Biomaterials in Transformative Deal - TipRanks
Celularity Licenses Biomaterials Portfolio to NexGel Partner - TipRanks
NexGel to Acquire Celularity Biomaterials Assets and Exclusive License in Deal Up to $35 Million - TradingView
Deal to triple NEXGEL (NASDAQ: NXGL) revenue and add profits - Stock Titan
Celularity Sells and Licenses Biomaterials Portfolio to NexGel in Deal Worth Up to $35 Million - TradingView
Celularity (Nasdaq: CELU) monetizes biomaterials in $35M license, pivots to longevity - Stock Titan
Biotechnology company Celularity Inc. recently announced a significant personnel change. - Bitget
NEXGEL, Inc. to Acquire Regenerative Biomaterial Portfolio from Celularity, Anticipating Tripled Revenue and Immediate Profitability - Quiver Quantitative
Biotechnology company Celularity Inc. (NASDAQ: CELU) has recently reached a strategic licensing agreement totaling 35 million dollars. - Bitget
NEXGEL Signs Definitive Agreement to License and Acquire - GlobeNewswire
Celularity Inc. Announces Strategic Partnership to Commercialize Biomaterials Portfolio, Generating Up to $35 Million in Payments - Quiver Quantitative
EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue - Benzinga
NEXGEL grabs Celularity biomaterials in move expected to turn a profit - Stock Titan
Celularity names John Sprague acting CFO following executive departure - Investing.com Nigeria
CELU SEC FilingsCelularity Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Breakouts Watch: Is Celularity Inc a defensive stockPrice Action & Safe Entry Point Alerts - baoquankhu1.vn
Will Celularity Inc. stock reach all time highs in 2026Weekly Loss Report & Reliable Price Action Trade Plans - Naître et grandir
Take Profit: Is Celularity Inc Equity Warrant impacted by rising ratesJuly 2025 Price Swings & Stock Market Timing Techniques - baoquankhu1.vn
Aug Shorts: What is Celularity Inc Equity Warrants revenue forecastJuly 2025 PreEarnings & Risk Controlled Swing Alerts - baoquankhu1.vn
Celularity names John Sprague acting CFO following executive departure By Investing.com - Investing.com India
Joseph Dossantos, Acting CFO, Leaves Celularity On Feb 27, 2026SEC Filing - TradingView
Celularity Inc Announces Departure of Joseph Dossantos as Svp, Finance, Effective February 27, 2026 - marketscreener.com
Celularity Inc. Shares Seek Catalysts Amid Sector-Watch Phase () - aktiencheck.de
CELU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CELUW SEC FilingsCelularity Inc 10-K, 10-Q, 8-K Forms - Stock Titan
CELUW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Portfolio Update: Is Celularity Inc Equity Warrant forming higher highs and higher lows2025 Volatility Report & Safe Capital Allocation Plans - baoquankhu1.vn
Celularity receives $12.2 million from sale of tax credits - Investing.com Nigeria
CELU PE Ratio & Valuation, Is CELU Overvalued - Intellectia AI
Aug Outlook: What are the risks of holding Celularity IncWeekly Risk Report & Fast Gain Swing Alerts - baoquankhu1.vn
CELUWCelularity Inc Latest Stock News & Market Updates - Stock Titan
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):